Project Grant K99CA300495
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $171K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The U.S. National Cancer Institute awarded a $855,249 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports DFCI's research to develop new approaches for targeting cell cycle proteins as potential cancer treatments. The key focus is on investigating how abnormal activation of cyclin-dependent kinases (CDKs) drives uncontrolled tumor cell proliferation, and exploring strategies to overcome limitations of...
- The U.S. National Cancer Institute (NCI) awarded a $151,040 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant supports research to investigate the role of interferon gamma (IFNγ) in promoting metastasis and immune evasion of triple negative breast cancer (TNBC). Specifically, the project aims to 1) elucidate the role of IFNγ in immune evasion during TNBC dissemination and metastatic...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support the development of a "Spatial Profiling-Based Immune Hub Perturbation Platform" to improve immunotherapy for colorectal cancer. The $710,361 award to J. David Gladstone Institutes will fund research to create a novel experimental framework to systematically test and prioritize candidate genes and therapies based on their ability to induce effective anti-tumor immune hubs -...
- The National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), awarded a $445,000 project grant to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant, awarded on January 22, 2025, supports DFCI's research on the molecular mechanisms of DNA double-strand break repair by homologous recombination, a critical process for cell survival and cancer prevention. The project aims to define the complex...
- This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $154,642 to the Sloan-Kettering Institute for Cancer Research in New York to conduct research on identifying conserved cancer-specific immunopeptide targets in metastatic colorectal cancer. The project aims to systematically elucidate the evolving immunopeptidome (peptides presented by HLA class I molecules) from patient-derived colorectal cancer organoids to reveal targetable...
- The federal Project Grant award in the amount of $159,304 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398). The award was granted to the Dana-Farber Cancer Institute, Inc. (DFCI) to support research on signaling pathways in tumoricidal macrophages in pancreatic cancer. The key objectives of the project include defining the role of deubiquitinases in regulating macrophage surface receptors that govern the recognition and phagocytosis...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...
- This federal Project Grant award of $312,892 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program. The grant supports research at Duke University to study the role of type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The goal is to understand how ILC3s impact the effectiveness of immune checkpoint inhibitor (ICI) therapy for advanced melanoma patients, as the majority do not respond to ICI treatment....
- The federal Project Grant award of $2,136,000.00 was provided by the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant supports research aimed at understanding and therapeutically targeting treatment-emergent neuroendocrine prostate cancer. As a leading academic medical research institution, DFCI will leverage its expertise in oncology, immunology, molecular...